A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

NCT00627627 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

56

Enrollment

INDUSTRY

Sponsor class

Stopped Redirect focus of the indication

Conditions

Breast Cancer

Interventions

DRUG: IPI-504

Sponsor

MedImmune LLC